Endurance training in patients with schizophrenia and healthy controls: differences and similarities
- 574 Downloads
The aims were to examine the feasibility of and adaptations to endurance training in persons diagnosed with schizophrenia and to address the question whether the principles and beneficial effects of endurance training established in the healthy population apply also to patients with schizophrenia. In this controlled interventional study, 22 patients with schizophrenia and 22 healthy controls performed a standardized aerobic endurance training on bicycle ergometers over 12 weeks. Another group of 21 patients with schizophrenia played table soccer. Endurance capacity was measured with incremental cycle ergometry before and after the intervention and 3 months later. A specific set of outcome parameters was defined. The training stimuli can be assumed to be similar in both endurance groups. Endurance capacity improved significantly in the endurance groups, but not in the table soccer group. Patients and healthy controls showed comparable adaptations to endurance training, as assessed by physical working capacity and maximal achieved power. Differences were found in changes of performance at a lactate concentration of 3 mmol/l. Endurance training was feasible and effective in both groups. The principles and types of training that are usually applied to healthy controls need to be verified in patients with schizophrenia. Nevertheless, patients benefited from endurance training in terms of improvement of endurance capacity and reduction in the baseline deficit in comparison with healthy controls. Therefore, endurance training should be implemented in future therapy programs. These programs need to pay special attention to the differences between patients with schizophrenia and healthy controls.
KeywordsAdaptations Endurance Sports therapy Psychiatry Schizophrenia Exercise
This study was supported by the Dorothea Schlözer Program at the University of Göttingen. We would like to express our sincere thanks to the family of Mrs. Ricarda Maucher for their generous financial support. We thank Jacquie Klesing, Board-certified Editor in the Life Sciences (ELS), for editing assistance with the manuscript and the Federal Ministry of Education and Research for the financial support of our research (01EE1407AE).
Compliance with ethical standards
Conflict of interest
K Keller-Varady, B. Malchow, T. Schneider-Axmann, U. Hillmer-Vogel, B. Adomßent and A. Niklas have no conflict of interest. A. Schmitt was an honorary speaker for TAD Pharma and Roche and has been a member of advisory boards for Roche. P. Falkai has been an honorary speaker for Janssen-Cilag, GE Healthcare, Otsuka, Servier, Takeda, Astra-Zeneca, Eli Lilly, Bristol-Myers-Squibb, Lundbeck, Pfizer, Bayer Vital, SmithKline Beecham, Wyeth and Essex. He was a member of the advisory boards of Janssen-Cilag, AstraZeneca, Eli Lilly, and Lundbeck. A. Hasan has been invited to scientific meetings by Lundbeck, Janssen-Cilag, and Pfizer has received a paid speakership from Desitin, Otsuka, and the Federal Union of German Associations of Pharmacists, and was member of the Roche Advisory Board. T. Wobrock has received paid speakerships from Alpine Biomed, AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, I3G, Janssen-Cilag, Novartis, Lundbeck, Roche, Sanofi-Aventis, Otsuka, and Pfizer, has accepted travel or hospitality not related to a speaking engagement from AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, Janssen-Cilag, and Sanofi-Synthelabo, has received research grants from AstraZeneca, Cerbomed, I3G, and AOK (health insurance company) and is a member of the advisory board of Janssen-Cilag.
The study has been approved by the local ethics committee and has been performed in accordance with the Declaration of Helsinki. All participants gave their informed consent prior to their inclusion. No personal data are published.
- 1.Deutsches Institut für Medizinische Dokumentation und Information (2013) ICD-10-GM Version 2014. Systematisches Verzeichnis. Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 10. Revision - German Modification (International Statistical Classification of Diseases and Related Health Problems)Google Scholar
- 2.Falkai P, Reich-Erkelenz D, Schmitt A (2014) Von der Pathophysiologie zur Entwicklung von Leitlinien und neuen Behandlungskonzepten der Schizophrenie (From pathophysiology to the development of guidelines and new therapeutic strategies in schizophrenia). Fortschr Neurol Psychiatr 82(4):186–190CrossRefPubMedGoogle Scholar
- 8.Antonovsky A (1979) Health, stress, and coping. New perspectives on mental and physical well-being. Jossey-Bass, San FranciscoGoogle Scholar
- 29.Steinacker JM, Liu Y, Reißnecker S (2002) Abbruchkriterien bei der Ergometrie (Termination criteria in ergometry). Deutsche Zeitschrift für Sportmedizin 53(7+8):228–229Google Scholar
- 32.Scharhag-Rosenberger F, Schommer K (2013) Die Spiroergometrie in der Sportmedizin (Exercise testing in sports medicine). Deutsche Zeitschrift für Sportmedizin 64(12):362–366Google Scholar
- 34.Faul F, Erdfelder E, Lang A et al (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Brain Res 39(2):175–191Google Scholar
- 48.Hottenrott K, Neumann G (2014) Trainingswissenschaft. Ein Lehrbuch in 14 Lektionen (Training science: a textbook with 14 lessons), 2nd edn. Meyer & Meyer Verlag, AachenGoogle Scholar
- 50.Bernard P, Romain AJ, Esseul E et al (2013) Barrières et motivation à l’activité physique chez l’adulte atteint de schizophrénie. Revue de littérature systématique (A systematic review of barriers to physical activity and motivation for adults with schizophrenia). Sci Sports 28(5):247–252CrossRefGoogle Scholar